362 related articles for article (PubMed ID: 37655228)
21. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies.
Vasquez A; Buraniqi E; Wirrell EC
Curr Opin Neurol; 2022 Apr; 35(2):145-154. PubMed ID: 35102126
[TBL] [Abstract][Full Text] [Related]
22. Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F; Jones K; Eltze C; Matricardi S
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
24. Current and future pharmacotherapy options for drug-resistant epilepsy.
Elkommos S; Mula M
Expert Opin Pharmacother; 2022 Dec; 23(18):2023-2034. PubMed ID: 36154780
[TBL] [Abstract][Full Text] [Related]
25. Update on rufinamide in childhood epilepsy.
Coppola G
Neuropsychiatr Dis Treat; 2011; 7():399-407. PubMed ID: 21792306
[TBL] [Abstract][Full Text] [Related]
26. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
27. Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy.
Samanta D
Children (Basel); 2022 Aug; 9(8):. PubMed ID: 36010049
[TBL] [Abstract][Full Text] [Related]
28. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
29. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
[TBL] [Abstract][Full Text] [Related]
30. Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials.
Pong AW; Ross J; Tyrlikova I; Giermek AJ; Kohli MP; Khan YA; Salgado RD; Klein P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):75-90. PubMed ID: 35341431
[TBL] [Abstract][Full Text] [Related]
31. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
34. Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? - A single centre long term follow up study.
Elbadri M; Bose S; Elkider M; Hayton T; McCorry D; Sumangala S; Wysota B; Samarasekera S
Epilepsy Behav; 2024 Jun; 157():109904. PubMed ID: 38908033
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
36. Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.
Vasquez A; Wirrell EC; Youssef PE
Expert Rev Neurother; 2023 Apr; 23(4):297-309. PubMed ID: 36975187
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
Sharawat IK; Panda PK; Panda P; Dawman L
Seizure; 2021 Oct; 91():296-307. PubMed ID: 34273668
[TBL] [Abstract][Full Text] [Related]
39. An overview of third-generation antiseizure drugs: Clobazam, lacosamide, rufinamide, and vigabatrin.
Spanaki MV; Barkley GL
Neurol Clin Pract; 2012 Sep; 2(3):236-241. PubMed ID: 29443301
[TBL] [Abstract][Full Text] [Related]
40. Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
Gresham J; Eiland LS; Chung AM
Neuropsychiatr Dis Treat; 2010 Oct; 6():639-45. PubMed ID: 20957124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
